Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| m6A-Mediated Biogenesis of circDDIT4 Inhibits Prostate Cancer Progression by Sequestrating ELAVL1/HuR. | Mol Cancer Res | 2023 | 37647111 | PubTator, text mining | PubMed |
| m6A methyltransferase METTL16 mediates immune evasion of colorectal cancer cells via epigenetically regulating PD-L1 expression. | Aging (Albany NY) | 2023 | 37647025 | PubTator, text mining | PubMed |
| Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells. | Exp Hematol Oncol | 2023 | 37644505 | PubTator, text mining | PubMed |
| FOXO1 regulates osteogenic differentiation of periodontal ligament stem cells through the METTL3 signaling pathway. | J Orthop Surg Res | 2023 | 37644500 | PubTator, text mining | PubMed |
| Deciphering RNA m6 A regulation in aging: Perspectives on current advances and future directions. | Aging Cell | 2023 | 37641471 | PubTator, text mining | PubMed |
| RBFOX2 recognizes N6-methyladenosine to suppress transcription and block myeloid leukaemia differentiation. | Nat Cell Biol | 2023 | 37640841 | PubTator, text mining | PubMed |
| Kar4 is required for the normal pattern of meiotic gene expression. | PLoS Genet | 2023 | 37639444 | PubTator, text mining | PubMed |
| Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer. | Front Immunol | 2023 | 37638051 | PubTator, text mining | PubMed |
| Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma. | Pharmaceutics | 2023 | 37631344 | PubTator, text mining | PubMed |
| Regulation of Notch1 Signalling by Long Non-Coding RNAs in Cancers and Other Health Disorders. | Int J Mol Sci | 2023 | 37628760 | PubTator, text mining | PubMed |
| Changes in m6A in Steatotic Liver Disease. | Genes (Basel) | 2023 | 37628704 | PubTator, text mining | PubMed |
| Oncogenic Targets Regulated by Tumor-Suppressive miR-30c-1-3p and miR-30c-2-3p: TRIP13 Facilitates Cancer Cell Aggressiveness in Breast Cancer. | Cancers (Basel) | 2023 | 37627217 | PubTator, text mining | PubMed |
| Cuproptosis- and m6A-Related lncRNAs for Prognosis of Hepatocellular Carcinoma. | Biology (Basel) | 2023 | 37626987 | PubTator, text mining | PubMed |
| Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation. | Cells | 2023 | 37626849 | PubTator, text mining | PubMed |
| The m6A modification-mediated OGDHL exerts a tumor suppressor role in ccRCC by downregulating FASN to inhibit lipid synthesis and ERK signaling. | Cell Death Dis | 2023 | 37626050 | PubTator, text mining | PubMed |
| Methylation across the central dogma in health and diseases: new therapeutic strategies. | Signal Transduct Target Ther | 2023 | 37620312 | PubTator, text mining | PubMed |
| METTL14 inhibits malignant progression of oral squamous cell carcinoma by targeting the autophagy-related gene RB1CC1 in an m6A-IGF2BP2-dependent manner. | Clin Sci (Lond) | 2023 | 37615536 | PubTator, text mining | PubMed |
| The hidden RNA code: implications of the RNA epitranscriptome in the context of viral infections. | Front Genet | 2023 | 37614818 | PubTator, text mining | PubMed |
| RNA modification: mechanisms and therapeutic targets. | Mol Biomed | 2023 | 37612540 | PubTator, text mining | PubMed |
| M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription. | Oncogene | 2023 | 37612524 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=46